Research Article

The PPAR-\(\gamma\) Agonist 15-Deoxy-\(\Delta^{12,14}\)-Prostaglandin J\(_2\) Attenuates Microglial Production of IL-12 Family Cytokines: Potential Relevance to Alzheimer’s Disease

Jihong Xu,1 Steven W. Barger,2 and Paul D. Drew1

1 Department of Neurobiology and Developmental Sciences, University of Arkansas for Medical Sciences, 4301 W. Markham Street, Little Rock, AR 72205, USA
2 Department of Geriatrics, University of Arkansas for Medical Sciences, 4301 W. Markham Street, Little Rock, AR 72205, USA

Correspondence should be addressed to Paul D. Drew, drewpauld@uams.edu

Received 22 March 2008; Accepted 22 April 2008

Recommended by Michael Racke

Accumulation of amyloid-\(\beta\) peptide (A\(\beta\)) appears to contribute to the pathogenesis of Alzheimer’s disease (AD). Therapeutic hope for the prevention or removal of A\(\beta\) deposits has been placed in strategies involving immunization against the A\(\beta\) peptide. Initial A\(\beta\) immunization studies in animal models of AD showed great promise. However, when this strategy was attempted in human subjects with AD, an unacceptable degree of meningoencephalitis occurred. It is generally believed that this adverse outcome resulted from a T-cell response to A\(\beta\). Specifically, CD4+ Th1 and Th17 cells may contribute to severe CNS inflammation and limit the utility of A\(\beta\) immunization in the treatment of AD. Interleukin (IL)-12 and IL-23 play critical roles in the development of Th1 and Th17 cells, respectively. In the present study, A\(\beta\)_1-42 synergistically elevated the expression of IL-12 and IL-23 triggered by inflammatory activation of microglia, and the peroxisome proliferator-activated receptor (PPAR)-\(\gamma\) agonist 15-deoxy-\(\Delta^{12,14}\)-PGJ\(_2\) (15d-PGJ\(_2\)) effectively blocked the elevation of these proinflammatory cytokines. Furthermore, 15d-PGJ\(_2\) suppressed the A\(\beta\)-related synergistic induction of CD14, MyD88, and Toll-like receptor 2, molecules that play critical roles in neuroinflammatory conditions. Collectively, these studies suggest that PPAR-\(\gamma\) agonists may be effective in modulating the development of AD.

Copyright © 2008 Jihong Xu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

1. INTRODUCTION

Alzheimer’s disease (AD) is a neurodegenerative disorder and the most common cause of dementia in the elderly. AD is characterized by progressive memory deficits, changes in personality, and cognitive decline. It is believed that abnormal accumulation of amyloid-\(\beta\) peptide (A\(\beta\)), either as a soluble factor or as extracellular aggregates, contributes to the development of AD [1–3]. Cleavage of amyloid precursor protein (APP) can produce amyloid-\(\beta\) peptide 1-42 (A\(\beta\)_1-42), the levels of which are correlated with neurotoxicity and development of AD. The connection between A\(\beta\) and AD symptoms is further strengthened by mouse models in which transgenic expression of the human A\(\beta\) precursor (APP) results in accumulation of A\(\beta\) and deficits in memory tests [4]. Preclinical investigations of anti-A\(\beta\) therapies have come to rely on such mice as a loose approximation of AD pathogenesis. The most successful anti-A\(\beta\) strategy demonstrated in these mice to date involves recruiting the immune system through vaccination. APP-transgenic mice that are immunized against A\(\beta\) at a young age never develop substantial A\(\beta\) deposits, and vaccination after deposition can even reverse a significant degree of the A\(\beta\) accumulation [5]. Most importantly, behavioral deficits are alleviated by such immunizations. These benefits correlate strongly with the titers of soluble antibody generated against A\(\beta\) [6–8], and passive immunization by injection of anti-A\(\beta\) antibody alone is also effective [9, 10]. Unfortunately, the first attempt to translate this vaccination approach to human AD patients generated iatrogenic meningoencephalitis in about 6% of individuals [11]. Mice can be induced to undergo similar reactions when overexpressing interferon (IFN)-\(\gamma\) [12], suggesting that immune responses tilted in favor of Th1 responses foster cell-mediated and/or inflammatory reactions to the vaccination. There is a considerable elaboration of inflammatory index in all AD brains [13, 14], including the activation of microglia;
apparently, this neuroinflammation is fostered by Aβ itself [15, 16]. It is possible that these proinflammatory actions of Aβ create conditions unfavorable for the development of humoral immune responses.

IL-12 family cytokines are heterodimeric proteins which include IL-12 and IL-23. IL-12 is composed of p40 and p35 subunits, and IL-23 is composed of the same p40 subunit together with a unique p19 subunit [17]. IL-12 plays a critical role in the differentiation of CD4+ Th1 lymphocytes. These Th1 lymphocytes stimulate cell-mediated immune responses important in clearing pathogens, including viruses and bacteria. Th1 lymphocytes produce IFN-γ which activates cells of the innate immune system and contributes to the clearance of these pathogens. IL-23 stimulates the differentiation of a unique set of CD4+ T lymphocytes. These cells are characterized by the production of the cytokine IL-17 and are termed Th17 lymphocytes [18]. Recent studies indicated that mice genetically ablated of the p19 subunit of IL-23 are resistant to the development of experimental autoimmune encephalomyelitis (EAE), whereas mice lacking the p35 subunit of IL-12 showed similar or more severe EAE than that observed in wild-type animals [19–21]. It thus appears that IL-12 and IL-23 each play important yet distinct roles in the development of immune responses that tend towards cell-mediated modalities which can include inflammation. Thus, suppressing the production of these cytokines may be effective in the treatment of inflammatory diseases.

Peroxisome proliferator-activated receptors (PPARs) are members of the nuclear hormone receptor family of transcriptional activators. Three PPAR subtypes exist (PPAR-α, PPAR-γ, and PPAR-β/δ), each exhibiting distinct patterns of tissue expression and ligand specificities [22]. The role of PPAR-γ in modulating adipogenesis and glucose metabolism is well established. Thiazolidinediones are PPAR-γ agonists that are currently used extensively in the treatment of type II diabetes. More recently, the role of PPAR-γ agonists in modulating immune responses, including immune responses in the CNS, has become appreciated. Nonsteroidal anti-inflammatory drugs (NSAIDs) have been shown to reduce AD risk and ameliorate microglial reactivity in AD brains [23]. Since NSAIDs bind to and activate PPAR-γ, resulting in reduced expression of proinflammatory genes, this receptor may mediate the observed anti-inflammatory effects of NSAIDs in AD brain. In addition, it has been demonstrated that the PPAR-γ agonists, pioglitazone and ibuprofen, reduced glial inflammation and Aβ1-42 levels in APPV7171 transgenic mice [24]. Collectively, these studies suggest that PPAR-γ agonists may be effective in the treatment of neurodegenerative diseases, including AD.

Pattern recognition receptors termed as Toll-like receptors (TLRs) play a critical role in the innate immune response to pathogen-associated molecular patterns (PAMPs) present in viruses, bacteria, and fungi [25]. They may also contribute to neuroinflammation triggered by endogenous ligands [25] or simply overexpression of the receptors alone [26]. A series of eleven TLRs have been identified in mice and humans, each capable of binding distinct PAMPs. The PAMP lipopolysaccharide (LPS) binds to TLR4 in association with another pattern recognition receptor termed as CD14. With the exception of TLR3, ligand binding to TLRs stimulates recruitment of the adaptor molecule Myd88, activating a well-defined signal transduction pathway that culminates in activation of the transcription factor NF-κB, which elevates expression of a variety of proinflammatory genes [27]. TLR4 has been suggested to play a role in regulating the pathogenesis of AD in humans [28, 29] and in animal models of AD [30]. This suggests that agents capable of altering Myd88-dependent TLR signaling may modulate the development of AD.

The current studies indicate that the PPAR-γ agonist 15d-PGJ2 suppresses the production of IL-12 and IL-23 by Aβ plus LPS-stimulated microglia. These cytokines play critical roles in Th1 and Th17 cell differentiation. These studies could have important implications concerning Aβ immunization as therapy for AD. In addition, we demonstrate that 15d-PGJ2 inhibits Aβ plus LPS stimulation of Myd88, CD14, and TLR2 expression by microglia, suggesting that this cyclopentenone prostaglandin inhibits Myd88-dependent signaling. This provides a potential mechanism by which the PPAR-γ agonist 15d-PGJ2 modulates the expression of proinflammatory cytokines.

2. MATERIALS AND METHODS

2.1. Reagents

15d-PGJ2 was obtained from Cayman Chemical Company (Ann Arbor, Mich, USA). Lipopolysaccharide and lectin, *Griffonia simplicifolia*, were obtained from Sigma (St. Louis, Mo, USA). Aβ1-42 was obtained from AnaSpec, Inc. (San Jose, Calif, USA). DMEM media, glucose, trypsin, and antibiotics used for tissue culture were obtained from BioWhittaker (Walkersville, Md, USA). OPI medium supplement was obtained from Sigma. Fetal bovine serum (FBS) was obtained from Hyclone (Logan, Utah, USA). GM-CSF was obtained from BD Pharmingen (San Diego, Calif, USA). N-2 supplement was obtained from Gibco Invitrogen Corporation (Carlsbad, Calif, USA). Glial fibrillary acidic protein (GFAP) was obtained from Dako (Carpinteria, Calif, USA). C57BL/6 mice were obtained from Harlan (Indianapolis, Ind, USA) and bred in house.

2.2. Cell culture

Primary mouse microglia cultures were obtained through a modification of the McCarthy and deVellis protocol [31]. Briefly, cerebral cortices from 1–3 day-old C57BL/6 mice were excised, meninges removed, and cortices minced into small pieces. Cells were separated by trypsinization followed by trituration of cortical tissue. The cell suspension was filtered through a 70 μm cell strainer to remove debris. Cells were centrifuged at 153 × g for 5 minutes at 4 °C, resuspended in DMEM medium containing 100% FBS, 1.4 mm L-glutamine, 100 U/mL penicillin, 0.1 mg/mL streptomycin, OPI medium supplement, and 0.5 ng/mL recombinant mouse GM-CSF, and plated into tissue culture flasks. Cells were allowed to grow to confluency (7–10 days) at 37°C/5%
CO₂. Flasks were then shaken overnight (200 rpm at 37 °C) in a temperature-controlled shaker to loosen microglia and oligodendrocytes from the more adherent astrocytes. These less adherent cells were plated for 2-3 hours and then lightly shaken to separate oligodendrocytes from the more adherent microglia. Microglia were seeded in 24-well plates or 6-well plates and incubated overnight at 37 °C/5% CO₂. After overnight incubation, cells were treated with 15d-PGJ₂ for 1 hour in the serum-free medium with N-2 supplement, and then stimulated with Aβ₁₋₄₂ and/or LPS for 6 or 24 hours. Aβ₁₋₄₂ peptides were dissolved in DMSO to prepare a 5 mM stock solution, which was aliquoted and stored at −80 °C. Aβ₁₋₄₂ stock solution was diluted with culture medium to a concentration of 0.1 mM, and set at room temperature for 12–18 hours before use. The final applied concentration of DMSO from Aβ was ≤0.2%. After the 24-hour stimulation, tissue culture supernatants were collected for enzyme-linked immunosorbent assay (ELISA), and cell viability was analyzed; 6 hours after stimulation, total RNA was collected for real-time quantitative RT-PCR (qRT-PCR) analysis. The purity of microglia cultures was greater than 95% as determined by immunohistochemical staining with the lectin, Griffonia simplicifolia. Astrocyte contamination of the microglial cultures was assessed by immunohistochemical staining with anti-GFAP.

2.3. Cell viability assay

Cell viability was determined by MTT reduction assay as described previously [32]. Optical densities were determined using a Spectromax 190 microplate reader (Molecular Devices, Sunnyvale, Calif, USA) at 570 nm. Results were reported as percent viability relative to untreated cultures.

2.4. Enzyme-linked immunosorbent assay (ELISA)

Cytokine (IL-12p40, IL-12p70, and IL-1β) levels in tissue culture media were determined by ELISA as described by the manufacturer (OptEIA Sets, Pharmingen, San Diego, Calif, USA). Cytokine IL-23 (p19/p40) levels in tissue culture media were determined by ELISA as described by the manufacturer (eBioscience, San Diego, Calif, USA). Optical densities were determined using a Spectromax 190 microplate reader (Molecular Devices, Sunnyvale, Calif, USA) at 450 nm. Cytokine concentrations in media were determined from standards containing known concentrations of the proteins.

2.5. RNA isolation and cDNA synthesis

Total RNA was isolated from microglia using the RNeasy Mini Kit (Qiagen Sciences, Md, USA). RNA samples were treated with DNaseI (Invitrogen, Carlsbad, Calif, USA) to remove any traces of contaminating DNA. The reverse transcription (RT) reactions were carried out using an iScript cDNA synthesis kit (Bio-Rad, Hercules, Calif, USA) according to the manufacturer’s instructions.

2.6. Real-time quantitative RT-PCR assay

IL-12p40, IL-12p35, IL-23p19, IL-1β, CD14, MyD88, TLR2, and TLR4 mRNAs were quantified by real-time PCR using an iCycler IQ multicolor real-time PCR detection system (Bio-Rad). All primers and TaqMan MGB probes (FAM-dye-labeled) were designed and synthesized by Applied Biosystems (Foster City, Calif, USA). The real-time PCR reactions were performed in a total volume of 25 μL using an iCycler kit (Bio-Rad). The levels of IL-12p40, IL-12p35, IL-23p19, IL-1β, CD14, MyD88, TLR2, and TLR4 mRNA expression in primary microglia were calculated after normalizing cycle thresholds against the “housekeeping” gene GAPDH, and are presented as the fold induction value (2−ΔΔCt) relative to LPS-stimulated microglia.

2.7. Statistics

Data were analyzed by one-way ANOVA followed by a Bonferroni posthoc test to determine the significance of difference.

3. RESULTS

3.1. Effects of 15d-PGJ₂ on IL-1β production by β-amyloid plus LPS-stimulated microglia

A variety of studies suggest that the inflammatory cytokine IL-1β plays a significant role in modulating the pathogenesis of AD [33]. In the present study, we investigated whether Aβ₁₋₄₂ plus a low dose of LPS could induce IL-1β production by primary mouse microglial cells. Our results showed that Aβ₁₋₄₂ alone did not induce microglia production of IL-1β protein (Figure 1(a)) and IL-1β mRNA (Figure 1(b)). LPS (10 ng/mL) alone stimulated microglial production of IL-1β protein and mRNA, while a combination of Aβ₁₋₄₂ and LPS synergistically induced the expression of IL-1β protein and mRNA. Interestingly, the PPAR-γ agonist 15d-PGJ₂ strongly suppressed induction of IL-1β in Aβ₁₋₄₂ plus LPS-stimulated primary microglial cells. The PPAR-γ agonist did not decrease the viability of these microglial cells compared to cells treated with Aβ₁₋₄₂ plus LPS as determined by MTT analysis (data not shown). Therefore, the effects of 15d-PGJ₂ on the production of IL-1β were not due to effects on cell viability. These studies suggest that 15d-PGJ₂ may suppress the production of IL-1β, an inflammation-related cytokine associated with the pathogenesis of AD.

3.2. Effects of 15d-PGJ₂ on IL-12 family cytokines by β-amyloid plus LPS-stimulated microglia

IL-12 family cytokines are believed to contribute to the differentiation of Th1 and Th17 cells. Aβ₁₋₄₂ alone had little or no effect on the production of IL-12 family cytokines by microglia. LPS (10 ng/mL) stimulated microglia to secrete IL-12 family cytokines including IL-12p40 (Figure 2(a)), IL-12p70 (Figure 2(b)), and IL-23 (Figure 2(c)). In the context of this inflammatory priming, Aβ₁₋₄₂ further increased microglial production of each of these IL-12 family proteins significantly. Furthermore, the PPAR-γ agonist 15d-PGJ₂
run in triplicate. At least three independent experiments were conducted. (b) Cells were pretreated for 1 hour with 15d-PGJ2 (2.5 μM), LPS (10 ng/mL), or Aβ1-42 (5 μM) plus LPS (10 ng/mL) was added as indicated, and 24 hours later, the concentration of IL-1β in the culture medium was determined. Values represent the mean ± s.e.m for a representative experiment run in triplicate. At least three independent experiments were conducted. (b) Cells were pretreated for 1 hour with 15d-PGJ2 (2.5 μM), LPS (5 ng/mL), or Aβ1-42 (10 μM) plus LPS (5 ng/mL) was added as indicated, and 6 hours later, total RNA was isolated. IL-1β mRNA levels were determined by real-time quantitative RT-PCR. Results are expressed as fold inductions in GAPDH normalized mRNA values versus levels in LPS-treated cells. Values are mean ± s.e.m of six samples derived from three independent experiments, with each experiment performed in duplicate. **P < .01 and ***P < .001 versus Aβ1-42 + LPS-treated cultures.

3.3. Effects of 15d-PGJ2 on expression of IL-12 family cytokine subunit mRNAs by β-amyloid plus LPS-stimulated microglia

Aβ1-42 alone had little or no effect on stimulating the expression of IL-12 family cytokine subunit mRNAs including IL-12p35 (Figure 3(a)), IL-12p40 (Figure 3(b)), and IL-23p19 (Figure 3(c)). Low doses of LPS (5 ng/mL) alone slightly induced the expression of these mRNAs. However, Aβ1-42 in combination with LPS elicited significantly higher levels of IL-12 family subunit mRNAs compared to microglia stimulated with LPS alone. Pretreatment with 15d-PGJ2 significantly suppressed the expression of IL-12 family subunit mRNAs. Thus, 15d-PGJ2 inhibits the expression of IL-12 family cytokines and the mRNAs that encode these proteins. IL-12 and IL-23 play critical roles in the differentiation of Th1 and Th17 cells, which may contribute to the inflammatory events that resulted in cessation of clinical trials involving immunization of Aβ in the treatment of AD. Thus, cotreatment with 15d-PGJ2 may increase the utility of Aβ immunotherapy for AD patients.

3.4. Effects of 15d-PGJ2 on expression of Toll-like receptor signaling

The MyD88-dependent TLR signaling pathway plays a critical role in modulating the response to PAMPs including LPS. We demonstrate that a combination of Aβ1-42 plus LPS significantly induced the expression of CD14 relative to microglia treated with LPS alone (Figure 4(a)). In addition, Aβ1-42 plus LPS also trended towards inducing MyD88 expression relative to each stimulus alone (Figure 4(b)). CD14 and MyD88 are critical intermediates in MyD88-dependent signaling. As we have demonstrated previously, LPS does not significantly induce the expression of TLR4, but does induce the expression of TLR2 [34]. Similarly, Aβ1-42 in combination with LPS did not induce microglial expression of TLR4 (Figure 4(c)), but did induce the expression of TLR2 (Figure 4(d)). Interestingly, 15d-PGJ2 inhibited Aβ1-42 plus LPS induction of MyD88, CD14, and TLR2 mRNA expression in microglia. These studies suggest that 15d-PGJ2 may suppress inflammatory responses stimulated by Aβ1-42 plus LPS by inhibiting MyD88-dependent TLR signaling.

4. DISCUSSION

AD currently affects over 200 million people worldwide. Disease incidence is expected to increase as the population ages, and the socioeconomic impact of AD is staggering. The disease is characterized in part by the presence of neuritic plaques which contain accumulations of insoluble Aβ. Vaccination with Aβ synthetic peptides in animal models of AD suggested that such immunizations may be effective in the treatment of AD in humans. For example, Aβ immunization of APP transgenic mice decreases the density and number of Aβ deposits in the brains of these mice. Decreased Aβ deposits in these mice are associated with decreased neuritic dystrophy and gliosis [7]. Intranasal administration of Aβ engenders humoral responses that include immunoglobulin isotypes consistent with a Th2 response, and this is associated with increased clearance of amyloid [35]. Significantly, active immunization against Aβ in APP transgenic mice decreases memory deficits in
**Figure 2:** 15d-PGJ₂ inhibits IL-12 family cytokines production by Aβ₁-42 plus LPS-activated microglia. Cells were pretreated for 1 hour with 15d-PGJ₂ (2.5 μM). Aβ₁-42 (5 μM), LPS (10 ng/mL), or Aβ₁-42 (5 μM) plus LPS (10 ng/mL) was added as indicated, and 24 hours later, the concentration of IL-12p40 (a), IL-12p70 (p35/p40) (b), and IL-23 (p19/p40) (c) in the culture medium was determined. Values represent the mean ± s.e.m for a representative experiment run in triplicate. At least three independent experiments were conducted. **P < .01 and ***P < .001 versus Aβ₁-42 + LPS-treated cultures.

**Figure 3:** 15d-PGJ₂ inhibits microglial mRNA expression of IL-12p40, IL-12p35, and IL-23p19 induced by Aβ₁-42 plus LPS. Cells were pretreated for 1 hour with 15d-PGJ₂ (2.5 μM). Aβ₁-42 (10 μM), LPS (5 ng/mL), or Aβ₁-42 (10 μM) plus LPS (5 ng/mL) was added as indicated, and 6 hours later, total RNA was isolated. IL-12p35 (a), IL-12p40 (b), and IL-23p19 (c) mRNA levels were determined by real-time quantitative RT-PCR. Results are expressed as fold inductions in GAPDH normalized mRNA values versus levels in LPS-treated cells. Values are mean ± s.e.m of six samples derived from three independent experiments, with each experiment performed in duplicate. *P < .05, **P < .01, and ***P < .001 versus Aβ₁-42 + LPS-treated cultures.
these mice [6, 35, 36]. Interestingly, passive administration of monoclonal antibodies specific for Aβ peptides is also effective in clearing Aβ and improving memory deficits in APP transgenic mice [37, 38]. This suggests that Aβ-specific antibodies produced following immunization are the critical factor mediating AD-like pathology in these animal models of AD. Three potential mechanisms have been suggested that may determine how anti-Aβ antibodies reduce Aβ deposits in the brains of APP transgenic mice. Aβ antibodies (1) may directly dissolve Aβ deposits, (2) may stimulate Fc-receptor-mediated phagocytosis of Aβ by microglia, and/or (3) may stimulate Aβ efflux from the brain to the plasma [3].

Animal studies indicating that Aβ immunization of APP transgenic mice reduced plaque burden in mice stimulated human clinical trials designed to evaluate the clinical efficacy of Aβ immunization in the treatment of AD. Small-scale phase I trials indicated apparent safety of Aβ immunization, and demonstrated that the majority of mild to moderate AD patients immunized in these studies produced anti-Aβ antibodies [39, 40]. However, subsequent larger-scale phase II clinical trials were halted when approximately 6% of Aβ immunized patients developed meningoencephalitis [11]. Postmortem evaluation indicated that Aβ immunization resulted in decreased plaque burden in the cortex of treated patients [41–43], and these brain regions were associated with abundant Aβ immunoreactive microglia, suggesting that these cells were involved in the removal of Aβ [43]. Interestingly, although anti-Aβ antibodies are believed to contribute to the reduction in Aβ plaques in AD patients, antibodies titers did not correlate with the development of meningoencephalitis [11, 40]. Several studies suggest that T cell responses to Aβ may have stimulated the development of meningoencephalitis in immunized AD patients [44–46]. Furthermore, a higher T cell reactivity to Aβ has been observed in some elderly and AD patients not immunized with Aβ. This suggests that the elderly population and AD

**Figure 4:** The effects of 15d-PGJ2 on microglial mRNA expression of CD14, MyD88, TLR4, and TLR2 induced by Aβ1-42 plus LPS. Cells were pretreated for 1 hour with 15d-PGJ2 (2.5 μM). Aβ1-42 (10 μM), LPS (5 ng/mL), or Aβ1-42 (10 μM) plus LPS (5 ng/mL) was added as indicated, and 6 hours later, total RNA was isolated. CD14 (a), MyD88 (b), TLR4 (c), and TLR2 (d) mRNA levels were determined by real-time quantitative RT-PCR. Results are expressed as fold inductions in GAPDH normalized mRNA values versus levels in LPS-treated cells. Values are mean ± s.e.m of six samples derived from three independent experiments, with each experiment performed in duplicate. * P < .05, ** P < .01, and *** P < .001 versus Aβ1-42 + LPS-treated cultures.
patients may exhibit increased susceptibility to the development of meningoencephalitis following Aβ vaccination [46]. Cases of meningoencephalitis were associated with increased infiltration of both CD4+ and CD8+ T cells [42]. However, it is generally believed that CD4+ Th1 cells triggered the development of meningoencephalitis following Aβ immunization [3]. The potential role of the recently described CD4+Th17 cells in the production of meningoencephalitis has not been evaluated. However, studies indicating that these cells play a critical role in the development of MS and other autoimmune disorders suggest that these cells may also play a role in the development of meningoencephalitis in Aβ immunized AD patients.

Our current studies indicate that the PPAR-γ agonist 15d-PGJ2 inhibits microglial production of IL-12 and IL-23, which play critical roles in the differentiation of Th1 and Th17 cells, respectively. This suggests that 15d-PGJ2 could potentially increase the efficacy and safety of Aβ immunization of AD patients by decreasing or abolishing the development of meningoencephalitis in these patients. Epidemiological studies indicated that nonsteroidal anti-inflammatory drugs (NSAIDs) reduced the risk of AD. Some NSAIDs are capable of activating PPAR-γ, suggesting that these drugs may modulate development of AD through activation of this receptor [47, 48]. The role of PPAR-γ in modulating AD is supported by studies indicating that ibuprofen reduced Aβ1-42 levels in APP transgenic mouse models of AD, while low levels of the thiazolidinedione pioglitazone stimulated a slight yet statistically insignificant reduction of Aβ1-42 levels in these mice [49]. In a later study, higher levels of pioglitazone decreased astrocyte and microglial activation and Aβ plaque burden in APP transgenic mice [24]. Similarly, the thiazolidinedione rosiglitazone also decreased Aβ1-42 levels in animal models of AD [50]. Collectively, these studies support a role for PPAR-γ in modulating AD pathology. Studies indicate that PPAR-γ activation suppresses expression of β-site of APP cleaving enzyme (BACE)-1, suggesting that PPAR-γ agonists may modulate AD pathogenesis at least in part by altering Aβ homeostasis [51]. Importantly, recent clinical studies demonstrated that rosiglitazone was effective in improving cognition in a subset of AD patients [52, 53]. The fact that rosiglitazone exhibits poor blood-brain barrier penetration suggests that this PPAR-γ agonist may act in the periphery and not directly in the CNS.

We and others have previously demonstrated that PPAR-γ agonists are capable of suppressing the activation of NF-kB, which is a potent transcriptional activator of a variety of genes encoding proinflammatory molecules. MyD88-dependent signaling results in the activation of NF-kB. In the current studies, we demonstrate that the PPAR-γ agonist 15d-PGJ2 suppressed microglial expression of MyD88 and CD14 which are critical intermediates in MyD88-dependent TLR signaling. In addition, we demonstrate that 15d-PGJ2 inhibits microglial expression of IL-1β, a cytokine believed to contribute to AD pathogenesis [33]. Thus, PPAR-γ agonists may act as general suppressors of classical activation of microglia. Since classically activated microglia produce neurotoxic molecules, suppression of microglial activation may protect against AD. However, it should also be noted that some form of microglial activation may help remove Aβ plaques from AD brains through phagocytosis. In addition, TLR and CD14 molecules have been suggested to contribute to—or alternatively protect against—the development of AD [30, 54, 55]. It clearly appears that microglia and microglial products modulate AD through a series of complex and potentially conflicting mechanisms.

In summary, we have demonstrated that the PPAR-γ agonist 15d-PGJ2 inhibits production of IL-12 and IL-23 by Aβ plus LPS-activated microglia. These cytokines regulate the differentiation of Th1 and Th17 cells, which may limit the efficacy of Aβ immunotherapy for the treatment of AD. Furthermore, we demonstrate that 15d-PGJ2 inhibits the production of IL-1β by microglia, a cytokine known to play a role in AD pathogenesis. Finally, we demonstrate that 15d-PGJ2 inhibits the expression of MyD88-dependent signaling intermediates, suggesting a mechanism by which this PPAR-γ agonist may suppress inflammation. Collectively, these studies contribute to the body of evidence indicating that PPAR-γ agonists may be effective in the treatment of AD.

ACKNOWLEDGMENTS

This work was supported by grants from the National Institutes of Health (NS42860, NS047546, and AG12411), and the Arkansas Biosciences Institute.

REFERENCES

[1] N. Abbas, I. Bednar, E. Mix, et al., “Up-regulation of the inflammatory cytokines IFN-γ and IL-12 and down-regulation of IL-4 in cerebral cortex regions of APPSWE transgenic mice,” Journal of Neuroimmunology, vol. 126, no. 1-2, pp. 50–57, 2002.
[2] D. Schenk, “Amyloid-β immunotherapy for Alzheimer’s disease: the end of the beginning,” Nature Reviews Neuroscience, vol. 3, no. 10, pp. 824–828, 2002.
[3] H. L. Weiner and D. Frenkel, “Immunology and immunotherapy of Alzheimer’s disease,” Nature Reviews Immunology, vol. 6, no. 5, pp. 404–416, 2006.
[4] D. Games, M. Buttini, D. Kobayashi, D. Schenk, and P. Seubert, “Mice as models: transgenic approaches and Alzheimer’s disease,” Journal of Alzheimer’s Disease, vol. 9, supplement 3, pp. 133–149, 2006.
[5] D. Morgan, “Immunotherapy for Alzheimer’s disease,” Journal of Alzheimer’s Disease, vol. 9, supplement 3, pp. 435–432, 2006.
[6] C. Janus, J. Pearson, J. McLaurin, et al., “Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer’s disease,” Nature, vol. 408, no. 6815, pp. 979–982, 2000.
[7] D. Schenk, R. Barbour, W. Dunn, et al., “Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse,” Nature, vol. 400, no. 6740, pp. 173–177, 1999.
[8] D. M. Wilcock, M. N. Gordon, K. E. Ugen, et al., “Number of Aβ inoculations in APP+PS1 transgenic mice influences antibody titers, microglial activation, and congophilic plaque levels,” DNA and Cell Biology, vol. 20, no. 11, pp. 731–736, 2001.
[9] M. H. Mohajeri, K. Saini, J. G. Schultz, M. A. Wollmer, C. Hock, and R. M. Nitsch, “Passive immunization against...
β-amylloid peptide protects central nervous system (CNS) neurons from increased vulnerability associated with an Alzheimer's disease-causing mutation,” *Journal of Biological Chemistry*, vol. 277, no. 36, pp. 33012–33017, 2002.

[10] D. M. Wilcock, A. Rojiani, A. Rosenthal, et al., “Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition,” *Journal of Neuroscience*, vol. 24, no. 27, pp. 6144–6151, 2004.

[11] J.-M. Orgogozo, S. Gilman, J.-F. Dartigues, et al., “Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization,” *Neurology*, vol. 61, no. 1, pp. 46–54, 2003.

[12] A. Monsonego, J. Imitola, S. Petrovic, et al., “Aβ-induced meningoencephalitis is IFN-γ-dependent and is associated with T cell-dependent clearance of Aβ in a mouse model of Alzheimer's disease,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 103, no. 13, pp. 5048–5053, 2006.

[13] M. T. Heneka and M. K. O'Banion, “Inflammatory processes in Alzheimer's disease,” *Journal of Neuroimmunology*, vol. 184, no. 1-2, pp. 69–91, 2007.

[14] J. C. S. Breitner, “The role of anti-inflammatory drugs in prevention and treatment of Alzheimer's disease,” *Annual Review of Medicine*, vol. 47, pp. 401–411, 1996.

[15] L. Meda, M. A. Cassatella, G. I. Szendrei, et al., “Activation of microglial cells by β-amylloid protein and interferon-γ,” *Nature*, vol. 374, no. 6523, pp. 647–650, 1995.

[16] C. A. Saura, G. Chen, S. Malkani, et al., “Conditional inactivation of presenilin 1 prevents amyloid accumulation and temporarily rescues contextual and spatial working memory impairments in amyloid precursor protein transgenic mice,” *Journal of Neuroscience*, vol. 25, no. 29, pp. 6755–6764, 2005.

[17] B. Oppmann, R. Lesley, B. Blom, et al., “Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12,” *Immunity*, vol. 13, no. 5, pp. 715–725, 2000.

[18] C. L. Langrish, B. S. McKenzie, N. J. Wilson, R. de Waal Malefyt, R. A. Kastelein, and D. J. Cua, “IL-12 and IL-23: master regulators of innate and adaptive immunity,” *Immunological Reviews*, vol. 202, pp. 96–105, 2005.

[19] B. Becher, B. G. Durell, and R. J. Noelle, “Experimental autoimmune encephalitis and inflammation in the absence of interleukin-12,” *Journal of Clinical Investigation*, vol. 110, no. 4, pp. 493–497, 2002.

[20] D. J. Cua, J. Sherlock, Y. Chen, et al., “Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain,” *Nature*, vol. 421, no. 6924, pp. 744–748, 2003.

[21] B. Gran, G.-X. Zhang, S. Yu, et al., “IL-12p35-deficient mice are susceptible to experimental autoimmune encephalomyelitis: evidence for redundancy in the IL-12 system in the induction of central nervous system autoimmune demyelination,” *Journal of Immunology*, vol. 169, no. 12, pp. 7104–7110, 2002.

[22] B. Desvergne and W. Wahli, “Peroxisome proliferator-activated receptors: nuclear control of metabolism,” *Endocrine Reviews*, vol. 20, no. 5, pp. 649–688, 1999.

[23] L. Gasparini, E. Ongini, and G. Wenk, “Non-steroidal anti-inflammatory drugs (NSAIDs) in Alzheimer's disease: old and new mechanisms of action,” *Journal of Neurochemistry*, vol. 91, no. 3, pp. 521–536, 2004.

[24] M. T. Heneka, M. Sastre, L. Dumitrescu-Ozimek, et al., “Acute treatment with the PPARγ agonist pioglitazone and ibuprofen reduces glial inflammation and Aβ1-42 levels in APPV7171 transgenic mice,” *Brain*, vol. 128, no. 6, pp. 1442–1453, 2005.

[25] K. Takeda, T. Kaisho, and S. Akira, “Toll-like receptors,” *Annual Review of Immunology*, vol. 21, pp. 335–376, 2003.

[26] N. Harri, C. J. Lewis, V. Vasko, et al., “Thyroid expression of a functional Toll-like receptor 3: overexpression can be induced by viral infection and reversed by phenylmethimazole and is associated with Hashimoto's autoimmune thyroiditis,” *Molecular Endocrinology*, vol. 19, no. 5, pp. 1231–1250, 2005.

[27] T. Kielian, “Toll-like receptors in central nervous system glial inflammation and homeostasis,” *Journal of Neuroscience Research*, vol. 83, no. 5, pp. 711–730, 2005.

[28] C. R. Balisteri, G. Candore, F. Listi, et al., “Role of TLR4 polymorphisms in inflammatory responses: implications for unsuccessful aging,” *Annals of the New York Academy of Sciences*, vol. 1119, no. 1, pp. 203–207, 2007.

[29] S. Walter, M. Letiembre, Y. Liu, et al., “Role of the toll-like receptor 4 in neuroinflammation in Alzheimer's disease,” *Cellular Physiology and Biochemistry*, vol. 20, no. 6, pp. 947–956, 2006.

[30] K. Tahara, H.-D. Kim, J.-J. Jin, J. A. Maxwell, L. Li, and K. Fukuchi, “Role of toll-like receptor signalling in Aβ uptake and clearance,” *Brain*, vol. 129, no. 11, pp. 3006–3019, 2006.

[31] K. D. McCarthy and J. de Vellis, “Preparation of separate astroglial and oligodendrogial cell cultures from rat cerebral tissue,” *Journal of Cell Biology*, vol. 85, no. 3, pp. 890–902, 1980.

[32] P. D. Drew and J. A. Chavis, “The cyclopentone prostaglandin 15-deoxy-Δ12,14 prostaglandin 1 inhibits nitric oxide, TNF-α, and IL-12 production by microglial cells,” *Journal of Neuroimmunology*, vol. 115, no. 1-2, pp. 28–35, 2001.

[33] R. E. Mrak and W. S. T. Griffin, “Common inflammatory mechanisms in Lewy body disease and Alzheimer disease,” *Journal of Neuropathology & Experimental Neurology*, vol. 66, no. 8, pp. 683–686, 2007.

[34] J. Xu and P. D. Drew, “ Peroxisome proliferator-activated receptor-γ agonists suppress the production of IL-12 family cytokines by activated glia,” *Journal of Immunology*, vol. 178, no. 3, pp. 1904–1913, 2007.

[35] M. Maier, T. J. Seabrook, N. D. Lazo, et al., “Short amyloid-β (Aβ) immunogens reduce cerebral Aβ load and learning deficits in an Alzheimer's disease mouse model in the absence of an Aβ-specific cellular immune response,” *Journal of Neuroscience*, vol. 26, no. 18, pp. 4717–4728, 2006.

[36] D. Morgan, D. M. Diamond, P. E. Gottschall, et al., “Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease,” *Nature*, vol. 408, no. 6815, pp. 982–985, 2000. Erratum in *Nature*, vol. 412, no. 6847, p. 660, 2001.

[37] F. Bard, C. Cannon, R. Barbour, et al., “Peripheral administration of anti-amylloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease,” *Nature Medicine*, vol. 6, no. 8, pp. 916–919, 2000.

[38] R. B. DeMattos, K. R. Bales, D. J. Cummins, J.-C. Dodart, S. M. Paul, and D. M. Holtzman, “Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer’s disease,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 98, no. 15, pp. 8850–8855, 2001.

[39] A. J. Bayer, R. Bullock, R. W. Jones, et al., “Evaluation of the safety and immunogenicity of synthetic Aβ42 (AN1792) in patients with AD,” *Neurology*, vol. 64, no. 1, pp. 94–101, 2005.
[40] S. Gilman, M. Koller, R. S. Black, et al., “Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial,” Neurology, vol. 64, no. 9, pp. 1553–1562, 2005.

[41] J. A. R. Nicoll, D. Wilkinson, C. Holmes, P. Steart, H. Markham, and R. O. Weller, “Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report,” Nature Medicine, vol. 9, no. 4, pp. 448–452, 2003.

[42] I. Ferrer, M. Boada Rovira, M. L. Sánchez Guerra, M. J. Rey, and F. Costa-Jussà, “Neuropathology and pathogenesis of encephalitis following amyloid-β immunization in Alzheimer’s disease,” Brain Pathology, vol. 14, no. 1, pp. 11–20, 2004.

[43] E. Masliah, L. Hansen, A. Adame, et al., “Aβ vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease,” Neurology, vol. 64, no. 1, pp. 129–131, 2005.

[44] H. L. Weiner and D. J. Selkoe, “Inflammation and therapeutic vaccination in CNS diseases,” Nature, vol. 420, no. 6917, pp. 879–884, 2002.

[45] A. Monsonego and H. L. Weiner, “Immunotherapeutic approaches to Alzheimer’s disease,” Science, vol. 302, no. 5646, pp. 834–838, 2003.

[46] A. Monsonego, V. Zota, A. Karni, et al., “Increased T cell reactivity to amyloid β protein in older humans and patients with Alzheimer disease,” Journal of Clinical Investigation, vol. 112, no. 3, pp. 415–422, 2003.

[47] T. Kielian and P. D. Drew, “Effects of peroxisome proliferator-activated receptor-γ agonists on central nervous system inflammation,” Journal of Neuroscience Research, vol. 71, no. 3, pp. 315–325, 2003.

[48] M. T. Heneka, G. E. Landreth, and D. L. Feinstein, “Role of peroxisome proliferator-activated receptor-γ in Alzheimer’s disease,” Annals of Neurology, vol. 49, no. 2, p. 276, 2001.

[49] Q. Yan, J. Zhang, H. Liu, et al., “Anti-inflammatory drug therapy alters β-amyloid processing and deposition in an animal model of Alzheimer’s disease,” Journal of Neuroscience, vol. 23, no. 20, pp. 7504–7509, 2003.

[50] W. A. Pedersen, P. J. McMillan, J. J. Kulstad, J. B. Leverenz, S. Craft, and G. R. Haynatzki, “Rosiglitazone attenuates learning and memory deficits in Tg2576 Alzheimer mice,” Experimental Neurology, vol. 199, no. 2, pp. 263–273, 2006.

[51] M. Sastre, I. Dewachter, G. E. Landreth, et al., “Nonsteroidal anti-inflammatory drugs and peroxisome proliferator-activated receptor-γ agonists modulate immunostimulated processing of amyloid precursor protein through regulation of β-secretase,” Journal of Neuroscience, vol. 23, no. 30, pp. 9796–9804, 2003.

[52] G. S. Watson, B. A. Cholerton, M. A. Reger, et al., “Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study,” American Journal of Geriatric Psychiatry, vol. 13, no. 11, pp. 950–958, 2005.

[53] M. E. Risner, A. M. Saunders, J. F. B. Altman, et al., “Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer’s disease,” The Pharmacogenomics Journal, vol. 6, no. 4, pp. 246–254, 2006.

[54] K. Fassbender, S. Walter, S. Kühl, et al., “The LPS receptor (CD14) links innate immunity with Alzheimer’s disease,” The FASEB Journal, vol. 18, no. 1, pp. 203–205, 2004.

[55] Y. Liu, S. Walter, M. Stagi, et al., “LPS receptor (CD14): a receptor for phagocytosis of Alzheimer’s amyloid peptide,” Brain, vol. 128, no. 8, pp. 1778–1789, 2005.